Introduction
============

Rheumatoid arthritis (RA) is an autoimmune disease of unknown aetiology that is characterized by recruitment and activation of inflammatory cells, synovial hyperplasia, and destruction of cartilage and bone. The proinflammatory cytokine TNFα is a key mediator in the pathogenesis of RA \[[@B1]\]. Etanercept (Enbrel^®^; Wyeth, Cambridge, MA, USA), a soluble TNFα receptor immunoglobulin fusion protein, has been recognized as a potent biological that neutralizes TNFα \[[@B2]-[@B4]\]. Clinical studies on the efficacy of TNFα-blocking agents clearly show that about 30% of patients receiving this expensive therapy are nonresponders \[[@B3],[@B5]\]. Although many efforts have been made to identify biomarkers for therapy response \[[@B6]\], no clinical or single laboratory marker exists today that allows a prediction of TNFα therapy efficacy in the individual patient. This lack of biomarker includes the newly identified specific serological marker for RA -- antibodies to cyclic citrullinated peptides \[[@B7],[@B8]\] -- as well as genetic markers \[[@B9]-[@B12]\].

A number of studies have shown that the expression of individual proteins -- particularly cytokines such as TNFα, IL-1β, IL-6 and IFNγ \[[@B13],[@B14]\], chemokines like IL-8 and MCP1, as well as matrix metalloproteinases such as MMP1 and MMP3 \[[@B15],[@B16]\] -- changes during etanercept therapy. These studies were limited to a small number of genes and their corresponding proteins, and were not able to identify new markers for characterizing disease activity or to determine discriminatory markers for the prediction of therapy outcome. Van der Pouw and coworkers \[[@B17]\] used gene expression profiling of synovial tissue to identify subsets of RA based on molecular criteria; see also Glocker and colleagues \[[@B18]\].

Lequerre and colleagues described changes in gene expression signatures of mononuclear cells in RA patients 3 months after the start of treatment that were correlated with the treatment response to another TNFα inhibitor, infliximab, in combination with methotrexate \[[@B19]\]. They reported a significant decrease of transcript levels of eight genes regulated by TNFα-dependent pathways in nonresponders, whereas transcript levels in responders did not change significantly but were slightly increased. The effects of infliximab treatment on the long-term changes of gene expression pattern of synovial tissue and their potential to predict the outcome of infliximab-treated RA patients was investigated by Lindberg and coworkers \[[@B20]\]. Differentially expressed genes were involved in processes such as chemotaxis, immune function, signal transduction and inflammatory responses. The value of tissue biopsies is still under debate, and biopsies repeated in quick succession are not feasible.

The present study uses global transcriptome analysis to determine RNA expression signatures in peripheral blood cells that specify the response to anti-TNFα therapy within the first days of treatment. The objective of our approach is to discover predictive markers by analysing gene sets that are distinctly regulated in the first 3 days after anti-TNF (etanercept) administration. This short time interval was chosen to identify initially perturbed gene expression not influenced by possible changes in comedication and environmental factors occurring during longer follow-up.

We report the application of established DNA array technology (Affymetrix^®^; St. Clara, CA, USA) to monitor changes in the expression levels of mononuclear cells from peripheral blood during etanercept treatment. Among about 14,500 genes, 42 candidate genes were found suitable for use as prognostic markers for the therapeutic outcome. Using supervised learning methods, pairs and triplets derived from these genes were found to have a high prognostic value -- reflected by prediction accuracies of over 89% for seven gene pairs and of 95% for 10 specific gene triplets.

Patients and methods
====================

Patients
--------

Nineteen patients (15 females, four males; mean age, 50.8 ± 11.0 years; mean duration of disease, 15.8 ± 9.4 years; all Caucasian) who met the American College of Rheumatology criteria for RA \[[@B21]\] were studied; for details, refer to Table [1](#T1){ref-type="table"}. More than three different disease-modifying antirheumatic drugs had failed to control disease activity before etanercept was administered. The study was approved by the ethics committee of the University of Magdeburg (71/99) and all patients were asked for written consent.

###### 

Patient characteristics

  Patient number   Age (years)   Gender   RA duration (years)   Disease-modifying antirheumatic drugs   Steroids (mg/day)   CCP-Ab (U/ml) (*t*~0~)   DAS28   X-ray progression   Response after 3 months   
  ---------------- ------------- -------- --------------------- --------------------------------------- ------------------- ------------------------ ------- ------------------- ------------------------- --------------
  1                77            Male     21                    None                                    5.0                 644                      5.45    4.69                No                        Nonresponder
  2                64            Male     27                    Leflunomide                             10.0                610                      5.18    4.61                No                        Nonresponder
  3                43            Female   33                    Methotrexate                            7.5                 81                       4.82    0.69                No                        Responder
  4                65            Female   45                    None                                    15.0                187                      6.00    6.44                Yes                       Nonresponder
  5                63            Female   8                     None                                    15.0                \>1,600                  5.83    8.37                Yes                       Nonresponder
  6                51            Female   17                    Methotrexate                            20.0                Negative                 6.16    4.40                Yes                       Nonresponder
  7                34            Female   9                     None                                    0.0                 806                      5.37    5.47                Yes                       Nonresponder
  8                44            Male     9                     None                                    15.0                Negative                 5.51    2.55                No                        Responder
  9                39            Male     1                     Methotrexate                            5.0                 Negative                 5.12    2.09                No                        Responder
  10               42            Female   29                    Methotrexate                            7.5                 Negative                 6.52    1.79                No                        Responder
  11               26            Female   2                     None                                    0.0                 Negative                 4.47    1.50                No                        Responder
  12               48            Female   24                    Leflunomide                             8.0                 429                      5.57    2.73                No                        Responder
  13               47            Female   13                    Cyclosporin A                           10.0                96                       7.11    5.29                No                        Responder
  14               53            Female   5                     Leflunomide                             8.0                 1064                     3.29    2.42                No                        Nonresponder
  15               62            Female   13                    Methotrexate                            0.0                 Neg.                     5.88    4.40                No                        Responder
  16               65            Female   2                     Sulfasalazine/hydroxychloroquin         15.0                \>1,600                  7.68    5.90                No                        Responder
  17               42            Female   14                    None                                    5.0                 61                       5.6     3.36                No                        Responder
  18               52            Female   8                     Methotrexate                            0.0                 436                      5.59    2.38                No                        Responder
  19               70            Female   14                    Leflunomide                             7.5                 855                      5.08    2.55                No                        Responder

Therapeutic response was defined clinically by changes of 28-joint-count Disease Activity Score (DAS28) determined at the beginning of the study (baseline) and 3 months after the start of etanercept treatment and additionally by X-ray analysis of hands and feet after 9 to 12 months. An improvement of the DAS28 by \>1.2 was considered a good response (if no progression of joint destruction were observed by X-ray analysis), a DAS28 reduction by ≤ 1.2 was considered a nonresponse. Serum antibodies to cyclic citrullinated peptide (CCP-Ab) were analysed using the Immunoscan RA ELISA CCP2 test (Euro-Diagnostica, Malmö, Sweden) according to the manufacturer\'s instructions (cutoff point = 25 U/ml). RA, rheumatoid arthritis.

Each patient was given a standard dose of 2 × 25 mg etanercept per week subcutaneously. Disease-modifying antirheumatic drugs and steroids remained unchanged in all patients for the first week of TNF-blocking therapy. Blood samples were taken at 7:00 a.m. before treatment (time *t*~0~; baseline), and at 72 hours after the first application of etanercept (time *t*~1~). Comedication was given after blood was taken.

Patients were assessed for overall disease activity using the 28-joint-count Disease Activity Score (DAS28) as described elsewhere \[[@B22]\]. Patients were categorized according to the European Leage against Rheumatism (EULAR) recommendations 3 months after the start of treatment, considering an improvement of the DAS28 \>1.2 a good response. X-ray scans were read by two independent experienced physicians, but the sequence of the X-ray scans was not blinded. After reviewing X-ray scans of hands and feet, the responder group was further characterized by the absence of new bone erosions after a time interval of at least 9 to 12 months of follow up.

Sample preparation
------------------

Peripheral blood mononuclear cells from 25 ml blood were separated on a Ficoll density gradient \[[@B23]\]. Using a FACSCalibur Flow Cytometer (Becton Dickinson, San Diego, CA, USA) the populations of CD3^+^, CD14^+^, CD19^+^and CD56^+^cells were determined to ensure comparability of peripheral blood mononuclear cell fractions of individual patients in the course of the study. Extraction of total RNA was performed using the Qiagen RNeasy kit (Qiagen, Hilden, Germany) including a DNA digest on-column according to the manufacturer\'s instructions.

Microarray analysis
-------------------

Affymetrix^®^microarray technology (Human Genome U133A gene chip) was used to analyse the expression levels of about 18,400 transcripts interrogated by more than 22,000 probe sets. The Human Genome U95A gene chip was applied to verify array data with selected patients. Labelling and microarray processing was performed according to the manufacturer\'s protocol. The scanning was carried out with 3 μm resolution, 488 nm excitation and 570 nm emission wavelengths employing the GeneArray Scanner (Affymetrix, St. Clara, CA, USA). The microarray data were stored according to the MIAME standard and are available from ArrayExpress \[[@B24]\] (accession number E-MTAB-11).

Quantitative real-time RT-PCR
-----------------------------

Expression levels of a subset of genes were measured by quantitative real-time RT-PCR performed with TaqMan assay reagents according to the manufacturer\'s instructions on a 7900 High Throughput Sequence Detection System (Applied Biosystems, Foster City, CA, USA) using predesigned primers and probes (GAPDH Hs99999905_m1, ICAM1 Hs00164932_m1, TNFAIP3 Hs00234713_m1, IL1β Hs00174097_m1, PDE4B Hs00277080_m1, PPP1R15A Hs00169585_m1, NFKBIA Hs00153283_m1, CCL4 Hs00237011_m1, IL-8 Hs00174103_m1, ADM Hs00181605_m1).

To calculate the gene expression change of selected genes, the ΔΔC~T~method was used. According to this method, the threshold cycle values (C~T~) for specific mRNA expression in each sample were normalized to the C~T~values of GAPDH mRNA in the same sample. This provides ΔC~T~values that were used to calculate the changes of gene expression levels. Thereby, for each gene, the gene expression change in the first 3 days (ΔΔC~T~) is defined by the difference of the ΔC~T~value at day 3 (*t*~1~) and the ΔC~T~value before treatment (*t*~0~).

Data processing and analysis
----------------------------

The microarray data were preprocessed using the Microarray Suite, version 5.0 (MAS5.0; Affymetrix, Santa Clara, CA, USA) in the default configuration, and were analysed by a set of algorithms.

First, an algorithm for calculation of a score *J*to rank differentially regulated genes. Basically, the *J*score introduced here is a *t*statistic, which compares the logarithm of the expression ratios *t*~1~/*t*~0~(signal log ratios) between responders and nonresponders. Thereby, the confidence intervals of the signal log ratios provided by MAS5.0 are used. In this way, the *J*score considers interindividual differences as well as measurement errors. A higher *J*score represents a more significant differential regulation. *J*\> 0 was used as the cutoff point to define genes as differentially regulated.

Second, an algorithm for learning of classifiers used for prediction of the therapy outcome on evaluation of the fold change of pairs and triplets of genes (Support-Vector Machine algorithm together with cross-validation by the leave-one-out method).

Finally, an algorithm for inference of hypothetic gene regulatory networks (modified LASSO algorithm).

These three algorithms are described in detail in Additional file [1](#S1){ref-type="supplementary-material"}.

Methods of multiple testing to control the type I error rates taking into account the large multiplicity (more than 22,000 probe sets) were not applied. This feature was circumvented by validating expression patterns of a selected set of genes (ICAM1, TNFAIP3, IL1B, PDE4B, PPP1R15A, NFKBIA, CCL4, IL8, ADM).

Results
=======

Clinical evaluation
-------------------

Before the start of treatment, all RA patients presented with a high disease activity reflected by a DAS28 (mean ± standard deviation) of 5.7 ± 0.7. Within 3 months of TNFα-blocking therapy, the disease activity decreased significantly looking at all patients as a group (DAS28 = 3.8 ± 2.1) (Table [1](#T1){ref-type="table"}).

Twelve patients (patients 3, 8 to 13, and 15 to 19) were characterized by a good therapy response, as indicated by a significant reduction of the DAS28 \>1.2 without progression of bone erosions as shown by X-ray scans of hands and feet. Three out of seven nonresponders (patients 4, 5 and 7) showed mild progression of bone erosion by X-ray reviewing. One patient (patient 6) was considered a nonresponder despite a good DAS28 response due to a progressive joint destruction as demonstrated by the X-ray scan. None of the clinical characteristics at baseline was significantly associated with the clinical outcome (Table [2](#T2){ref-type="table"})

###### 

Comparison of clinical characteristics at baseline

  Characteristic                                        Responder         Nonresponder      *P*value
  ----------------------------------------------------- ----------------- ----------------- ----------
  Age (years)                                           48.33 (± 12.29)   58.14 (± 13.67)   0.125^a^
  Gender (male)                                         2/12              2/7               0.603^b^
  Rheumatoid arthritis duration (years)                 13.5 (± 10.46)    18.86 (± 13.93)   0.353^a^
  Steroids (mg/d)                                       6.71 (± 5.16)     10.43 (± 6.80)    0.195^a^
  28-joint-count Disease Activity Score baseline        5.75 (± 0.94)     5.33 (± 0.97)     0.364^a^
  Antibodies to cyclic citrullinated peptide-negative   5/12              1/7               0.333^b^
  Disease-modifying antirheumatic drugs                                                     
   None                                                 3/12              4/7               0.326^b^
   Leflunomide                                          2/12              2/7               0.603^b^
   Methotrexate                                         5/12              1/7               0.333^b^
   Cyclosporin A                                        1/12              0/7               1.000^b^
   Sulfasalazine/hydroxychloroquin                      1/12              0/7               1.000^b^

Both patient groups show similar characteristics before therapy onset (mean ± standard deviation and number of patients, respectively). Statistical tests (^a^two-sample *t*test, ^b^exact Fisher test) were applied to check whether any of the parameters are associated with clinical outcome.

Gene expression profiling using the U133A array
-----------------------------------------------

Application of Affymetrix DNA-chip technology to monitor changes in the expression profile of about 14,500 known genes in peripheral blood mononuclear cells during anti-TNFα therapy reflected a differential response by our patients as evinced by changes in the DAS28 greater than 1.2. Forty-two genes represented by 46 probe sets (Table [3](#T3){ref-type="table"}) were found to be differentially regulated in therapy responders and nonresponders. The majority (40 probe sets representing 36 genes) was stronger downregulated or lesser upregulated in responders compared with nonresponders.

###### 

Differentially regulated genes (probe sets) in responders and nonresponders

  Symbol                                            Accession number   Probe set      Function                                                    *J*value   Direction^a^   Significance^b^
  ------------------------------------------------- ------------------ -------------- ----------------------------------------------------------- ---------- -------------- -----------------
  Transcription/regulation of transcription                                                                                                                                 
   TNFAIP3                                          AI738896           202643_s\_at   TNFα-induced protein 3                                      1.1830     \-             \+
   TNFAIP3                                          NM_006290          202644_s\_at   TNFα-induced protein 3                                      0.9956     \-             \+
   NFKBIA                                           AI078167           201502_s\_at   NFκB enhancer in B-cell inhibitor alpha                     0.4762     \-             \+
   RUNX1                                            L21756             211620_x\_at   Runt-related transcription factor 1                         0.3940     \+             \+
   JUN                                              BG491844           201464_x\_at   c-jun proto-oncogene                                        0.1352     \-             \-
   ZFP36L2                                          AI356398           201367_s\_at   Zinc finger protein 36, C3H type-like 2                     0.1308     \-             \+
   SRRM2                                            AI655799           208610_s\_at   Serine/arginine repetitive matrix 2                         0.0081     \+             \-
   ASCL1                                            AW950513           213768_s\_at   Achaete-scute complex-like 1                                0.0444     \-             \-
   FOXO3A                                           AF041336           210655_s\_at   Forkhead box O3A                                            0.0131     \-             \-
  Immune response                                                                                                                                                           
   IL1B                                             NM_000576          205067_at      IL-1β                                                       0.9716     \-             \+
   IL1B                                             M15330             39402\_        IL-1β                                                       0.9523     \-             \+
   CCL4                                             NM_002984          204103_at      Chemokine (C-C motif) ligand 4                              0.8002     \-             \+
   CCL3                                             NM_002983          205114_s\_at   Chemokine (C-C motif) ligand 3                              0.4621     \-             \+
   CXCR4                                            AF348491           211919_s\_at   Chemokine (C-X-C motif) receptor 4                          0.2589     \-             \-
   CXCL2                                            M57731             209774_x\_at   Chemokine (C-X-C motif) ligand 2                            0.2532     \-             \+
   LTF                                              NM_002343          202018_s\_at   Lactotransferrin                                            0.1884     \-             \-
   PBEF1                                            NM_005746          217739_s\_at   Pre-B-cell colony-enhancing factor 1                        0.0751     \-             \-
   IGHA1                                            S55735             217022_s\_at   Immunoglobulin heavy constant alpha 1                       0.0475     \-             \-
   IER3                                             NM_003897          201631_s\_at   Immediate early response 3                                  0.0284     \-             \-
  Receptors, cell surface antigens, cell adhesion                                                                                                                           
   ADAM12                                           AU145357           215613_at      ADAM metallopeptidase domain 12 (meltrin alpha)             0.5538     \-             \+
   ICAM1                                            AI608725           202637_s\_at   Intercellular adhesion molecule 1 (CD54)                    0.5399     \-             \-
   SCN2B                                            U87555             210364_at      Sodium channel, voltage-gated, type II, beta                0.2294     \+             \+
  Signal transduction                                                                                                                                                       
   PDE4B                                            L20966             211302_s\_at   Phosphodiesterase 4B, cAMP-specific                         0.4374     \-             \+
   RAPGEF1                                          NM_005312          204543_at      Rap guanine nucleotide-exchange factor 1                    0.2890     \-             \+
   MYO10                                            AI1561354          216222_s\_at   Myosin X                                                    0.2066     \-             \+
   PTPRD                                            NM_002839          205712_at      Protein tyrosine phosphatase, receptor type, D              0.1822     \+             \+
   SOCS1                                            AI056051           209999_x\_at   Suppressor of cytokine signaling 1                          0.1239     \-             \-
   PDE4B                                            NM_002600          203708_at      Phosphodiesterase 4B, cAMP-specific                         0.0593     \-             \+
  Metabolism                                                                                                                                                                
   LGALS13                                          NM_013268          220440_at      Lectin, galactose-binding, soluble, 13 (galectin 13)        0.5013     \+             \+
   SNCA                                             BG260394           204466_s\_at   Synuclein, alpha                                            0.0568     \-             \-
   CHST3                                            AB017915           32094_at       Carbohydrate sulfotransferase 3                             0.0366     \-             \+
  Cellular and oxidative stress response                                                                                                                                    
   CROP                                             AW089673           208835_s\_at   Cisplatin resistance-associated overexpressed protein       0.7500     \+             \+
   PPP1R15A                                         NM_014330          202014_at      Protein phosphatase 1, regulatory (inhibitor) subunit 15A   0.6886     \-             \+
   PPP1R15A                                         U83981             37028_at       Protein phosphatase 1, regulatory (inhibitor) subunit 15A   0.5939     \-             \-
   DDIT4                                            M_019058           202887_s\_at   DNA-damage-inducible transcript 4                           0.2366     \-             \-
   SOD2                                             W46388             215223_s\_at   Superoxide dismutase 2, mitochondrial                       0.0724     \-             \-
   ADM                                              NM_001124          202912_at      Adrenomedullin                                              0.0459     \-             \+
  Transport                                                                                                                                                                 
   ATP2A3                                           AF068220           207521_s\_at   ATPase, Ca^2+^transporting, ubiquitous                      0.227      \-             \-
   CHRND                                            NM_000751          207024_at      Cholinergic receptor, nicotinic, delta                      0.1977     \-             \+
  Protein binding                                                                                                                                                           
   PIGO                                             AC004472           214990_at      Phosphatidylinositol glycan, class O                        0.5216     \-             \+
   IBRDC3                                           W27419             36564_at       IBR domain containing 3                                     0.1194     \-             \+
   EBP49                                            NM_001978          204505_s\_at   Erythrocyte membrane protein band 4.9 (dematin)             0.0804     \-             \-
   FBX07                                            NM_012179          201178_at      F-box protein 7                                             0.0080     \-             \-
  Unknown                                                                                                                                                                   
   FSD1                                             NM_024333          219170_at      Fibronectin type III and SPRY domain containing 1           0.2935     \-             \+
   HCG4P6                                           AF036973           215974_at      HLA complex group 4 pseudogene 6                            0.1518     \-             \+
   C20orf103                                        NM_013361          219463_at      Chromosome 20 open reading frame 103                        0.0022     \-             \-

Genes were identified as differentially regulated using a modified *t*-statistic score, *J*(see Additional file [1](#S1){ref-type="supplementary-material"}), calculated using signal log ratios at *t*~1~versus *t*~0~considering 12 responders and seven nonresponders to etanercept therapy. ^a^Direction denotes genes as stronger downregulated or lesser upregulated in responders compared with nonresponders (-), and *vice versa*(+). ^b^+, significance approved by the resampling method with the modified *t*statistic on the significance level α = 0.05 (see Data processing and analysis section).

The mean of expression signals at *t*~0~averaged over the responders (*n* = 12) and over the nonresponders (*n* = 7) did not differ significantly in these genes, with the exception of SCN2B with *P*\< 0.05 (Additional file [1](#S1){ref-type="supplementary-material"}, Table S3a). A subset of 23 genes (represented by 27 probe sets) were approved to be differentially expressed according to the permutation test, with a significance level α = 0.05.

All 1,035 gene pairs resulting from the 46 preselected probe sets of differentially expressed genes were examined according to their ability to clearly discriminate responders and nonresponders. For each gene pair, a set of classifiers was constructed and evaluated by cross-validation using the leave-one-out method. Seven gene pairs (Table [4](#T4){ref-type="table"}) produced a prediction accuracy *Q*\> 89%. Baseline levels of the selected gene pairs were not reliable in predicting the outcome as reflected by *Q*~t0log~values between 42.1% and 79.0% (Additional file [1](#S1){ref-type="supplementary-material"}, Table S4a). The classification performance was also insufficient when using expression levels at *t*~1~(*Q*~t1log~). Figure [1](#F1){ref-type="fig"} shows a representative example of a discriminating gene pair (*Q*= 90.5%). Only one of the 19 patients (patient 16 -- preclassified to be a clinical responder) matches with the pool of nonresponders. Owing to a DAS28 score that remained reasonably high, patient 16 eventually resembles a nonresponder according to EULAR criteria.

###### 

Combinations of genes predictive for the clinical outcome: gene pairs and gene triplets

  Combination    Gene 1    Gene 2         Gene 3    *Q*(%)                                  
  -------------- --------- -------------- --------- -------------- --------- -------------- ------
  Gene pair                                                                                 
   1             TNFAIP3   202643_s\_at   RAPGEF1   204543_at                               90.5
   2             TNFAIP3   202643_s\_at   PTPRD     205712_at                               90.5
   3             TNFAIP3   202644_s\_at   PTPRD     205712_at                               90.5
   4             IL1B      205067_at      LGALS13   220440_at                               90.5
   5             CCL4      204103_at      ADAM12    215613_at                               89.5
   6             ADAM12    215613_at      CCL3      205114_s\_at                            89.5
   7             FSD1      219170_at      HCG4P6    215974_at                               89.5
  Gene triplet                                                                              
   1             CCL4      204103_at      PDE4B     211302_s\_at   RAPGEF1   204543_at      99.0
   2             PDE4B     211302_s\_at   RAPGEF1   204543_at      CXCR4     211919_s\_at   98.0
   3             CCL4      204103_at      PIGO      214990_at      RAPGEF1   204543_at      96.8
   4             CCL4      204103_at      FSD1      219170_at      RAPGEF1   204543_at      96.8
   5             CCL4      204103_at      CCL3      205114_s\_at   RAPGEF1   204543_at      96.8
   6             PDE4B     211302_s\_at   RUNX1     211620_x\_at   RAPGEF1   204543_at      96.8
   7             CCL4      204103_at      LGALS13   220440_at      RAPGEF1   204543_at      95.8
   8             TNFAIP3   202643_s\_at   CCL4      204103_at      RAPGEF1   204543_at      95.8
   9             TNFAIP3   202643_s\_at   PDE4B     211302_s\_at   RAPGEF1   204543_at      95.8
   10            TNFAIP3   202644_s\_at   PDE4B     211302_s\_at   RAPGEF1   204543_at      95.8

Gene pairs and triplets of genes with prognostic relevance for etanercept therapy in rheumatoid arthritis determined using support vector machines based on 46 selected probe sets of differentially regulated genes. Gene pairs with prediction accuracy *Q*\> 89% and triplets of genes with prediction accuracy *Q*\> 95% are shown. For gene function refer to Table 3.

![Gene expression changes of a representative predictive gene pair. Shown is the pair PTPRD \[205712_at\], TNFAIP3 \[202643_s\_at\]. The pair is presented in Table 4 with a prediction accuracy of 90.5% determined using the support vector machine algorithm (signal log ratios for *t*~1~versus *t*~0~: (○) 12 responders and (●) seven nonresponders, defined due to clinical response; bars denote the confidence intervals of the signal log ratios). Patient 16 was classified as a nonresponder based on gene expression data, but as a responder from clinical status.](ar2419-1){#F1}

Finally, the separation strength of classification could be further improved by taking triplets of differentially regulated genes. Thereto, 15,180 triplets as combinations of the 46 selected probe sets were computed. Ten triplets were identified to express a prediction accuracy \>95%. Figure [2](#F2){ref-type="fig"} shows a three-dimensional plot of one representative triplet gene set as presented in Table [4](#T4){ref-type="table"}.

![Gene expression changes of a representative predictive gene triplet. The triplet of genes TNFAIP3, PDE4B, RAPGEF1 is shown. The triplet is presented in Table 4 with a prediction accuracy of 95.8% determined using support vector machines (signal log ratios for *t*~1~versus *t*~0~: (○) 12 responders and (●) seven nonresponders).](ar2419-2){#F2}

Validation of GeneChip U133A microarray data
--------------------------------------------

Expression levels of a subset of genes were measured by quantitative real-time PCR for each patient and were compared with Human Genome arrays U133A and U95A (patients 1 to 11). As shown in Table [5](#T5){ref-type="table"}, high correlations between the datasets obtained by three different methods of gene expression analysis were found.

###### 

Validation of array data by real-time quantitative RT-PCR

  Gene       Probe set      Correlation coefficient                     
  ---------- -------------- ------------------------- -------- -------- --------
  ICAM1      202637_s\_at   32640_at                  0.9329   0.8916   0.8560
  TNFAIP3    202643_s\_at   595_at                    0.9437   0.9537   0.9792
  IL1B       39402_at       39402_at                  0.9443   0.9623   0.9667
  PDE4B      211302_s\_at   33705_at                  0.8880   0.9583   0.6307
  PPP1R15A   37028_at       37028_at                  0.9519   0.9869   0.7649

Pearson correlation coefficients between real-time quantitative RT-PCR data (-ΔΔC~T~*t*~1~versus *t*~0~) and the microarray data from the GeneChip U133A and U95A for five selected genes found to be differentially regulated in responders and nonresponders are presented.

In eight out of 20 genes selected for real-time quantitative RT-PCR (NFKBIA, CCL4, IL8, IL1B, PDE4B, TNFAIP3, PPP1R15A and ADM), the means of the gene expression change differed significantly for responders and nonresponders at significance level α \< 0.05, as shown in Table [6](#T6){ref-type="table"}. For all these genes, the means of the gene expression changes measured by quantitative real-time RT-PCR averaged over the seven nonresponders are positive, whereas those averaged over the 12 responders are negative or less positive than for the nonresponders.

###### 

Gene expression analysis by real-time quantitative RT-PCR

  Gene       Responder   Nonresponder   *P*value               
  ---------- ----------- -------------- ---------- ----------- -------
  NFKBIA     -0.227      (± 0.749)      1.053      (± 1.128)   0.008
  CCL4       -0.142      (± 1.184)      1.144      (± 0.924)   0.025
  IL8        -0.025      (± 1.871)      2.429      (± 2.489)   0.028
  IL1B       -0.595      (± 1.680)      1.487      (± 2.191)   0.032
  TNFAIP3    0.002       (± 0.895)      1.266      (± 1.510)   0.034
  PDE4B      -0.276      (± 0.846)      0.534      (± 0.544)   0.037
  PPP1R15A   -0.280      (± 0.935)      0.825      (± 1.225)   0.040
  ADM        -0.931      (± 1.289)      0.279      (± 1.016)   0.049

Data shown are the changes of gene expression (-ΔΔC~T~*t*~1~versus *t*~0~; mean ± standard deviation) of eight selected genes averaged over the 12 responders and seven nonresponders, and the corresponding *P*values determined by two-sample *t*test comparing the means of responders and nonresponders.

Genetic network modelling
-------------------------

A hypothetic dynamic network was calculated (Figure [3](#F3){ref-type="fig"}) to reveal the underlying regulatory network that characterizes responders to the TNFα inhibitor therapy. This responder model accentuates IL-6 functions through the highest number of edges (vertex degree of 22) (see Additional file [1](#S1){ref-type="supplementary-material"}).

![Visualization of the inferred dynamic gene regulatory network for the responder group. Each gene is represented by a node, and gene regulatory interactions are shown by directed edges. Solid lines, activating effects; dashed lines, inhibitory effects. The hypothesized network was reconstructed from quantitative real-time RT-PCR data by the modified LASSO method.](ar2419-3){#F3}

Discussion
==========

The goal of the present study was to identify reliable biomarkers for predicting therapy outcomes in RA patients treated with the TNFα-blocking agent etanercept. Changes of the pre-existing gene activities were monitored following the neutralization of TNFα. The Affymetrix microarray technique produced reliable semiquantitative results confirmed by comparing real-time RT-PCR results of selected genes with Affymetrix microarray results.

By applying a newly implemented criterion that takes into account the confidence intervals of the signal log ratios of gene expression \[[@B25]\] (see Additional file [1](#S1){ref-type="supplementary-material"}), 42 candidate genes (46 probe sets) were found to be differentially regulated following a single application of etanercept (Table [2](#T2){ref-type="table"}). The early downregulation of expression levels secondary to TNFα neutralization includes genes involved in different pathways and cellular processes such as TNFα signalling via NFκB (TNFAIP3, NFKBIA), NFκB-independent signalling via cAMP (PDE4B), and in the regulation of cellular and oxidative stress response (PPP1R15A, DDIT4, CROP, adrenomedullin, MnSOD). The differential expression of this gene set was associated with distinct clinical responses as evinced by changes in overall disease activities 3 months after the start of treatment. The majority of the identified genes (40 probe sets) were found to be downregulated in responders compared with nonresponders. The differential expression of 27 probe sets was confirmed to be significant using a resampling method. Most importantly, changes in the expression profiles of these selected genes, particularly of pairs or triplets of genes detected 3 days after the start of treatment, were identified as being closely associated with the outcome of therapy (Additional file [1](#S1){ref-type="supplementary-material"}, Tables S3a, S3b). Flow cytometry analysis ruled out that changes of the expression pattern within the first 3 days of treatment were due to an altered cellular distribution of peripheral blood cells.

Two patients (patients 2 and 16) who were not predicted properly were classified as outliers by correlating clinical data and gene expression changes. Patient 2 presents a highly destructive RA, making it difficult to distinguish joint destructions in RA from destructions due to secondary osteoarthritis. Patient 16 displays the highest DAS28 score of the cohort, making it difficult to classify the patient as responder when reaching a DAS28 of 5.9, which is exceptionally high. The stratification of these two cases is hampered in their overall assessment by the limitation of tools such as the DAS28.

In contrast to changes in gene expression pattern in the first days of treatment, gene expression signatures at a single time point, here at baseline, were not reliable in predicting the clinical outcome. Diversities between RA patients on the genetic, molecular and clinical levels \[[@B17]\] evinced by the presence of autoantibodies (rheumatoid factor, anti-cyclic citrullinated peptide antibodies) \[[@B26]\] probably underline the difficulty to predict therapy outcome solely based on pretreatment expression profiles. Eventually, the differences seen in transcriptional responses to etanercept administration might either reflect the state or type of the RA disease or describe epigenomic/genomic variabilities within the patient cohort.

The reconstructed dynamic network representing responders (Figure [3](#F3){ref-type="fig"}) indicates that not only TNFα may play a significant role in the response to TNFα inhibitors such as etanercept. IL-6-related functionalities seem to play a key role in the responder model, while TNFα-related mechanisms are underscored in nonresponders. The functional dynamics of TNFα and IL-6 might be crucial for the outcome of an etanercept therapy. In biological terms, functionalities of anti-TNFα responses observed in nonresponding patients in comparison with responding patients might emerge due to a differential dynamic regulation of TNFα and of TNFα-dependent target gene expression, possibly also flanked by TNFα-independent mechanisms.

Responders show complex network functions of cytokines including IL-6-mediated, IL-1-mediated, and IL-8-mediated activities. Once TNFα signals are therapeutically downregulated, cytokines such as IL-6 and IL-8 become visible, possibly modulating and eventually attenuating TNF-driven inflammatory processes. This observation is in line with reports on the pleiotropic/anti-inflammatory actions of IL-6 \[[@B27]\], which demonstrated the role of endogenous IL-6 in controlling the levels of proinflammatory cytokines in acute inflammatory responses. The particular role of IL-6 in inflammatory conditions such as RA is presently considered in therapeutic interventions that target IL-6 or its receptor \[[@B28]\].

Differential changes in the expression pattern following anti-TNFα treatment can most probably be attributed to the presence of genetic heterogeneities within the group of RA patients, suggesting the presence of polymorphisms (single nucleotide polymorphisms) and/or epigenetic differences (DNA methylation patterns) in the identified genes. These polymorphisms -- found in regulatory gene elements of central cytokines or downstream cascades -- or the combination of single nucleotide polymorphisms as well as other types of genetic variations within these differentially regulated or associated genes, such as copy number variations, might possibly turn out to be responsible for mediating therapeutic responses as observed. This hypothesis is supported by findings that some population differences in gene expressions are attributable to allele frequency differences, in particular at regulatory polymorphisms \[[@B29]\].

Conclusion
==========

The present findings demonstrate that it is possible to predict the response of RA patients to anti-TNFα therapy at an early stage of treatment with likelihood \>89% (95%) based on differentially expressed gene pairs or gene triplets. By knowing gene sets differentially regulated by TNFα-blocking therapy, additional epigenetic/genetic marker information might be obtained to circumvent the necessity of conducting cost-intensive expression studies. Along these lines, the real challenge of the listed predictory gene sets (pairs and triplets) is to validate in prospectively designed clinical trials the true accuracy and clinical value of this approach in selecting patients that profit most from a TNFα-blocking therapy.
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